New Adjuvant Treatment for Early Breast Cancer Tops SPT Week in Review

5. DNA Marker May Predict Poor Outcomes, Treatment Resistance in Multiple Myeloma

A certain type of DNA rearrangement that is rarely tested for may be a predictor of prognosis in multiple myeloma. Read more.

4. FDA Approves New Treatment for Transthyretin Amyloid Cardiomyopathy

Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments. Read more.

3. Tagraxofusp Shows High Response Rate in Rare, Deadly Blood Cancer

Treatment with tagraxofusp yielded high response rates in patients with blastic plasmacytoid dendritic cell neoplasm. Read more.

2. FDA OKs First Treatment for Children with Lambert-Eaton Myasthenic Syndrome

Amifampridine (Ruzurgi, Jacobus) is the first treatment approved specifically for pediatric patients 6 to 17 years of age with Lambert-Eaton myasthenic syndrome. Read more.

1. FDA Approves Adjuvant Treatment for HER2-Positive Early Breast Cancer

Ado-trastuzumab emtansine (Kadcyla) is currently the only antibody-drug conjugate approved for the treatment of HER2-positive early and metastatic breast cancer. Read more.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.
Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.